The views expressed on this podcast are those of the participants, not of Roiders' News.

Robert of Kennedy Jr., he came out.

And he's going to help make America healthy again.

Thank you. America healthy again. And now he's a great guy and he really means it.

He wants to do some things and we're going to let him go to it.

I just said, but Bobby, leave the oil to me.

Big Pharma giants are facing an uncertain future in their biggest market. President-elect Donald Trump has selected vaccine skeptic Robert F. Kennedy Jr. to run the country's healthcare department,

which could lead to dramatic changes in the way drugs

are priced in the US, as well as how much the country spends on creating new vaccinations

for infectious diseases like Mpox. Trump may argue that RFK will help cut the US's spending on healthcare,

which is projected a balloon to nearly $5 trillion this year, but the prospect of lower prices

in the world's largest drug market could create systemic problems for the pharmaceutical industry.

How companies like Pfizer, Novartis, and Roche can navigate a less friendly environment is the

focus of this week's Viewsroom.

Welcome back to the Viewsroom, the weekly podcast from Reuters Breaking Views that invites

you, the listener, into a lively debate about the biggest stories of the week.

I'm your host, Jonathan Guilford.

And I'm Amy Dunlund. So Amy, RFK Jr. is, how do I put this lightly, not a conventional choice to head up a developed economy health

system. Obviously, this is part of, let's say, a questionable discourse that has been going on for a while

about whether vaccines are tied to autism, but also brings in more prosaic issues about pricing. I mean, how do you think about it?

Is it possible to even get your arms around this yet? Or is it just like, oh my goodness,

everybody's trying to deal with how out of the usual this pick is? Oh, this is it. I mean,

...